AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
IN8bio shares surge 12.94% intraday after presenting promising DeltEx glioblastoma trial results showing improved survival rates.
ByAinvest
Monday, Nov 24, 2025 1:33 pm ET1min read
IN8bio surged 12.94% intraday after announcing positive clinical trial results for its gamma-delta T cell therapy, DeltEx™, in glioblastoma patients, demonstrating improved survival rates compared to standard care. The data, presented during the trading session, highlighted the therapy’s potential as a breakthrough treatment, boosting investor confidence in the company’s pipeline. A separate corporate presentation disclosed a $200 million mixed shelf offering and a narrowed Q3 net loss, but the clinical trial news was the primary catalyst for the sharp intraday rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet